Anebulo Pharmaceuticals, Inc. ( (ANEB) ) has released its Q4 earnings. Here is a breakdown of the information Anebulo Pharmaceuticals, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cannabis-induced toxicity, with its lead product candidate, selonabant, targeting acute cannabinoid intoxication.
In its latest earnings report for the fourth quarter and fiscal year 2025, Anebulo Pharmaceuticals highlighted significant progress in its clinical trials and financial performance. The company has initiated a Phase 1 study of an intravenous formulation of selonabant, aimed at treating acute cannabis-induced toxicity in children, and received a grant from the National Institute on Drug Abuse to support this study.
Key financial metrics for the quarter showed operating expenses of $2.3 million, up from $1.3 million the previous year, leading to a net loss of $2.1 million. For the full fiscal year, operating expenses rose to $9.2 million, with a net loss of $8.5 million, slightly higher than the previous year’s loss. The company ended the fiscal year with $11.6 million in cash and cash equivalents.
Strategically, Anebulo is considering a reverse stock split as part of a potential going-private transaction, aiming to reduce the number of its record holders. This move is part of a broader strategic review process, although no definitive decisions have been made.
Looking ahead, Anebulo Pharmaceuticals is optimistic about the potential of selonabant as an emergency antidote for cannabis-induced toxicity in children, with ongoing collaborations with the FDA and NIDA to expedite its development and approval process.